Advertisement

Cancer Chemotherapy and Pharmacology

, Volume 77, Issue 3, pp 595–603 | Cite as

Phase I/II study of nab-paclitaxel plus gemcitabine for chemotherapy-naive Japanese patients with metastatic pancreatic cancer

  • Hideki UenoEmail author
  • Masafumi Ikeda
  • Makoto Ueno
  • Nobumasa Mizuno
  • Tatsuya Ioka
  • Yasushi Omuro
  • Takako Eguchi Nakajima
  • Junji Furuse
Original Article

Abstract

Purpose

Efficacy and safety of nab-paclitaxel plus gemcitabine have not been clarified in Japanese patients with metastatic pancreatic cancer. No pharmacokinetic profile of co-administration of nab-paclitaxel and gemcitabine has been reported. We conducted a phase I/II study of the efficacy, safety, and pharmacokinetics in Japanese patients with metastatic pancreatic cancer.

Methods

The patients were administered 125 mg/m2 nab-paclitaxel followed by 1000 mg/m2 gemcitabine on day 1, 8, and 15 every 4 weeks. Treatment was continued until disease progression, unacceptable adverse events, or withdrawal of consent, whichever occurred first. The primary endpoints were tolerability in phase I and overall response rate according to RECIST in phase II.

Results

A total of 34 patients were enrolled. At the time of 1-year follow-up analysis since the last patient enrollment, the objective response rate by independent review committee was 58.8 % (20 of 34 patients; 95 % confidence interval [CI], 40.7–75.4 %). The median progression-free survival and median overall survival were 6.5 months (95 % CI, 5.1–8.3) and 13.5 months (95 % CI, 10.6—not reached), respectively. Main adverse drug reactions of grade 3 or higher were neutropenia (70.6 %), leukopenia (55.9 %), anemia (14.7 %), lymphocytopenia (14.7 %), thrombocytopenia (14.7 %), and peripheral sensory neuropathy (11.8 %). There were no treatment-related deaths and no marked differences in pharmacokinetics of combined paclitaxel and gemcitabine in historical comparison between co-administration and monotherapies.

Conclusions

Nab-paclitaxel plus gemcitabine regimen showed highly promising efficacy with manageable safety profile under careful observation and with appropriate supportive care in Japanese patients with metastatic pancreatic cancer.

Clinical trial number

JapicCTI-121987.

Keywords

Combination chemotherapy Gemcitabine Nab-paclitaxel Pancreatic cancer Pharmacokinetics 

Notes

Acknowledgments

We thank all of the participating patients and their families, as well as the investigators and clinical research coordinators. We are grateful to Yutaka Ariyoshi, Yusuke Tanigawara, and Keisuke Aiba, who served as members of the Data and Safety Monitoring Committee, and Atsushi Sato and Kouki Yoshikawa as members of the Independent Review Committee.

Funding

This study was funded by Taiho Pharmaceutical Co., Ltd.

Compliance with ethical standards

Conflict of interest

The study was designed under the responsibility of Taiho Pharmaceutical. Study drug was provided by Taiho Pharmaceutical. In collaboration with all authors, Taiho Pharmaceutical designed the study, analyzed and interpreted the data, and edited the report. Data were recorded at participating clinical centers and maintained by Taiho Pharmaceutical. All authors had full access to all of the data in the study and had final responsibility for the decision to submit for publication. We also thank to Takanori Tanase for his contribution as biostatistician, Taiho Pharmaceutical, for overall management of the trial and drafting the manuscript. Hideki Ueno received honoraria from Taiho Pharmaceutical; he has also received research funding from Taiho Pharmaceutical, OncoTherapy Science, Eli Lilly Japan, Merck Serono Japan, and Zeria Pharmaceutical. Masafumi Ikeda received honoraria from Taiho Pharmaceutical, Bayer Yakuhin, Bristol Myers, Abbott Japan, Yakult Honsha, and Novartis Pharmaceutical; he has also received research funding from Taiho Pharmaceutical, Bayer Yakuhin, Merck Serono, Kyowa Hakko Kirin, Yakult Honsha, Eli Lilly Japan, Chugai Pharmaceutical, OncoTherapy Science, Boehringer Ingelheim, Kowa, Ono Pharmaceutical, Eisai, AstraZeneca, Glaxo Smithkline, Pfizer Japan, Takeda Pharmaceutical, and Zeria Pharmaceutical. Makoto Ueno received honoraria from Taiho Pharmaceutical; he has also received research funding from Taiho Pharmaceutical, Merck Serono, and Zeria Pharmaceutical. Nobumasa Mizuno received research funding from Taiho Pharmaceutical, Merck Serono, AstraZeneca, Zeria Pharmaceutical, and Takeda Pharmaceutical. Tatsuya Ioka received honoraria from Taiho Pharmaceutical and Chugai Pharmaceutical; he has also receibved research funding from Taiho Pharmaceutical, Merck Serono, AstraZeneca, Zeria Pharmaceutical, Nippon Zoki Pharmaceutical, Yakult Honsha, and Glaxo Smithkline. Yasushi Omuro received research funding from Taiho Pharmaceutical, MSD, Ono Pharmaceutical, Eli Lilly Japan, Chugai Pharmaceutical, and Merck Serono. Takako E Nakajima received honoraria from Taiho Pharmaceutical; she has also received research funding from Taiho Pharmaceutical and Eli Lilly Japan. Junji Furuse received honoraria from Taiho Pharmaceutical, Chugai Pharmaceutical, Bayer Yakuhin, Eisai, Ono Pharmaceutical, Zeria Pharmaceutical, Eli Lilly Japan, Boehringer Ingelheim, Novartis Pharmaceutical, Kyowa Hakko Kirin, Yakult Honsha, Merck Serono, and FUJIFILM Corporation; he has also received research funding from Taiho Pharmaceutical, Ono Pharmaceutical, OncoTherapy Science, Bayer Yakuhin, Eli Lilly Japan, Chugai Pharmaceutical, Glaxo Smithkline, Takeda Pharmaceutical, Zeria Pharmaceutical, and Merck Serono.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.

Supplementary material

280_2016_2972_MOESM1_ESM.docx (45 kb)
Supplementary material 1 (DOCX 44 kb)

References

  1. 1.
    Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A (2015) Global cancer statistics 2012. CA Cancer J Clin 65:87–108CrossRefPubMedGoogle Scholar
  2. 2.
    Japanese Ministry of Health, Labour and Welfare (2012) Statistical investigation result [in Japanese]. http://www.mhlw.go.jp/toukei/saikin/hw/jinkou/kakutei12/index.html. Accessed 27 Nov 2013
  3. 3.
    Burris HA 3rd, Moore MJ, Andersen J et al (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15:2403–2413PubMedGoogle Scholar
  4. 4.
    Moore MJ, Goldstein D, Hamm J et al (2007) Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25:1960–1966CrossRefPubMedGoogle Scholar
  5. 5.
    Ueno H, Ioka T, Ikeda M et al (2013) Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study. J Clin Oncol 31:1640–1648CrossRefPubMedGoogle Scholar
  6. 6.
    Conroy T, Desseigne F, Ychou M et al (2011) FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364:1817–1825CrossRefPubMedGoogle Scholar
  7. 7.
    Desai N, Trieu V, Yao Z et al (2006) Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin- bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin Cancer Res 12:1317–1324CrossRefPubMedGoogle Scholar
  8. 8.
    Gradishar WJ, Tjulandin S, Davidson N et al (2005) Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 23:7794–7803CrossRefPubMedGoogle Scholar
  9. 9.
    Socinski MA, Bondarenko I, Karaseva NA et al (2012) Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial. J Clin Oncol 30:2055–2062CrossRefPubMedGoogle Scholar
  10. 10.
    Hosein PJ, de Lima Lopes G, Jr Pastorini VH et al (2013) A phase II trial of nab-Paclitaxel as second-line therapy in patients with advanced pancreatic cancer. Am J Clin Oncol 36:151–156CrossRefPubMedGoogle Scholar
  11. 11.
    Von Hoff DD, Ramanathan RK, Borad MJ et al (2011) Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. J Clin Oncol 29:4548–4554CrossRefGoogle Scholar
  12. 12.
    Von Hoff DD, Ervin T, Arena FP et al (2013) Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 369:1691–1703CrossRefGoogle Scholar
  13. 13.
    Goldstein D, El-Maraghi RH, Hammel P et al (2015) nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial. J Natl Cancer Inst Jan 31 107(2):dju413CrossRefGoogle Scholar
  14. 14.
    NCCN (2015) NCCN Clinical Practice Guidelines in Oncology. Pancreatic adenocarcinoma version 2. NCCN. http://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf. Accessed 28 May 2015
  15. 15.
    Ando M, Yonemori K, Katsumata N et al (2012) Phase I and pharmacokinetic study of nab-paclitaxel, nanoparticle albumin-bound paclitaxel, administered weekly to Japanese patients with solid tumors and metastatic breast cancer. Cancer Chemother Pharmacol 69:457–465CrossRefPubMedGoogle Scholar
  16. 16.
    Interview form of gemzar® injection, 11 edn (2013) [in Japanese]. Eli Lilly Japan K.K. https://www.lilly.co.jp/lillyanswers/data/if/if_gem.pdf. Accessed 28 May 2015
  17. 17.
    Rochat B (2005) Role of cytochrome P450 activity in the fate of anticancer agents and in drug resistance: focus on tamoxifen, paclitaxel and imatinib metabolism. Clin Pharmacokinet 44:349–366CrossRefPubMedGoogle Scholar
  18. 18.
    Bouffard DY, Laliberté J, Momparler RL (1993) Kinetic studies on 2′,2′-difluorodeoxycytidine (Gemcitabine) with purified human deoxycytidine kinase and cytidine deaminase. Biochem Pharmacol 45:1857–1861CrossRefPubMedGoogle Scholar
  19. 19.
    Buccheri G, Ferrigno D, Tamburini M (1996) Karnofsky and ECOG performance status scoring in lung cancer: a prospective, longitudinal study of 536 patients from a single institution. Eur J Cancer 32A:1135–1141CrossRefPubMedGoogle Scholar
  20. 20.
    Japanese society of medical oncology (2012) Practical Guideline of Febrile Neutropenia (FN): Clinical Question 9, Treatment. [In Japansese]. Nankodo Co., Ltd. Tokyo, pp 22–23Google Scholar
  21. 21.
    Ueno H, Okusaka T, Funakoshi A et al (2007) A phase II study of weekly irinotecan as first-line therapy for patients with metastatic pancreatic cancer. Cancer Chemother Pharmacol 59:447–454CrossRefPubMedGoogle Scholar
  22. 22.
    Okusaka T, Funakoshi A, Furuse J et al (2008) A late phase II study of S-1 for metastatic pancreatic cancer. Cancer Chemother Pharmacol 61:615–621CrossRefPubMedGoogle Scholar
  23. 23.
    Okusaka T, Funakoshi A, Furuse J et al (2011) Phase II study of erlotinib plus gemcitabine in Japanese patients with unresectable pancreatic cancer. Cancer Sci 102:425–431CrossRefPubMedGoogle Scholar
  24. 24.
    Okusaka T, Ikeda M, Fukutomi A et al (2014) Phase II study of FOLFIRINOX for chemotherapy-naıve Japanese patients with metastatic pancreatic cancer. Cancer Sci 105:1321–1326PubMedCentralCrossRefPubMedGoogle Scholar
  25. 25.
    Yanagimoto H, Ioka T, Ikeda M et al (2012) Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study [In Japansese]. In: Paper presented at: 42th annual meeting of Japanese Pancreas SocietyGoogle Scholar
  26. 26.
    Garrido-Laguna I, Hidalgo M (2015) Pancreatic cancer: from state-of-the-art treatments to promising novel therapies. Nat Rev Clin Oncol 12:319–334CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2016

Authors and Affiliations

  • Hideki Ueno
    • 1
    Email author
  • Masafumi Ikeda
    • 2
  • Makoto Ueno
    • 3
  • Nobumasa Mizuno
    • 4
  • Tatsuya Ioka
    • 5
  • Yasushi Omuro
    • 6
  • Takako Eguchi Nakajima
    • 7
  • Junji Furuse
    • 8
  1. 1.Hepatobiliary and Pancreatic Oncology DivisionNational Cancer Center HospitalTokyoJapan
  2. 2.Department of Hepatobiliary and Pancreatic OncologyNational Cancer Center Hospital EastKashiwaJapan
  3. 3.Division of Hepatobiliary and Pancreatic Medical OncologyKanagawa Cancer CenterYokohamaJapan
  4. 4.Department of GastroenterologyAichi Cancer Center HospitalNagoyaJapan
  5. 5.Department of Hepatobiliary and Pancreatic OncologyOsaka Medical Center for Cancer and Cardiovascular DiseasesOsakaJapan
  6. 6.Department of Medical OncologyTokyo Metropolitan Cancer and Infectious Diseases Center Komagome HospitalTokyoJapan
  7. 7.Department of Medical OncologySt.Marianna University School of Medicine HospitalKawasakiJapan
  8. 8.Department of Medical OncologyKyorin University School of MedicineTokyoJapan

Personalised recommendations